personalized medicine

Research in Review

High-Intensity End-of-Life Care Common Among Pediatric Cancer Patients

12/13/2016

JCP Editors

Children with cancer frequently receive high-intensity end-of-life care, despite advances in palliative medicine, according to the results of a retrospective study published in Journal of Clinical...

...

12/13/2016

Journal of Clinical Pathways

Slow Implementation of Value-Based Care

11/30/2016

JCP Editors

In 2012, the American Board of Internal Medicine launched the Choosing Wisely campaign, which attempts to curb wasteful medical spending by limiting the use of unnecessary tests and procedures. Prominent medical...

In...

11/30/2016

Journal of Clinical Pathways

Research in Review

Combining Targeted Therapies Provides Optimal Treatment for CML

11/17/2016

JCP Editors

Using mathematical modeling, researchers have determined the best combination and sequencing of targeted therapies for the treatment of chronic myeloid leukemia (CML). Their results have been published in PLOS...

Using...

11/17/2016

Journal of Clinical Pathways

Research in Review

Recurrence Score Assay Helping to Guide Breast Cancer Decision Making

10/26/2016

JCP Editors

Use of the 21-gene recurrence score (RS) assay is helping clinicians and patients decide which treatments are best for them, according to a large-scale survey of more than 3000 women treated for breast...

Use of...

10/26/2016

Journal of Clinical Pathways

Department

Better Cervical and Endometrial Cancer Outcomes With IMRT

10/03/2016

JCP Editors

Patients treated with intensity-modulated radiation therapy (IMRT) for cervical or endometrial cancer have fewer adverse events and experience better quality of life than those treated with conventional radiation...

...

10/03/2016

Journal of Clinical Pathways

Department

SBRT Safer, Equally Effective for Newly-Diagnosed Prostate Cancer

09/29/2016

JCP Editors

High-dose stereotactic body radiotherapy (SBRT) for men with newly-diagnosed low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates,...

...

09/29/2016

Journal of Clinical Pathways

Department

Hypofractionated Radiation Therapy Safer, Halves Treatment Time in NSCLC

09/27/2016

JCP Editors

Hypofractionated radiation therapy is less toxic and just as effective as conventional radiation therapy in patients with non-small cell lung cancer (NSCLC), according to research presented at the 58th Annual Meeting...

...

09/27/2016

Journal of Clinical Pathways

Research in Review

HAPs Prevent Treatment Resistance in EGFR+ NSCLC

09/12/2016

JCP Editors

Adding a hypoxia-activated prodrug (HAP) to standard care for epidermal growth factor receptor-positive non-small cell lung cancer may help to delay treatment resistance, according to a study published in PLOS...

Adding...

09/12/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz: Week of September 4-10

09/08/2016

JCP Editors

In a Viewpoint found in the most recent issue of Journal of Clinical Pathways, Dr Stephen McKenna contends that oncology patient-reported outcome measures (PROMs) are restrictive because they focus too much on a...

In a...

09/08/2016

Journal of Clinical Pathways

Research in Review

Response-Guided Neoadjuvant Chemotherapy Cost Effective for Breast Cancer

09/07/2016

JCP Editors

Response-guided neoadjuvant chemotherapy (RG-NACT) is more cost effective than conventional NACT for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according...

...

09/07/2016

Journal of Clinical Pathways